Pradeep J Nathan

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. doi request reprint The potent M(1) receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction
    Pradeep J Nathan
    Medicines Discovery and Development, GlaxoSmithKline Clinical Unit, Cambridge, UK
    Int J Neuropsychopharmacol 16:721-31. 2013
  2. ncbi request reprint The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H₃ receptor antagonist in patients with mild to moderate Alzheimer's disease: a preliminary investigation
    Pradeep J Nathan
    GSK Clinical Unit Cambridge, Addenbrooke s Centre for Clinical Investigations, Cambridge Biomedical Campus, Cambridge CB2 2GG, UK
    Curr Alzheimer Res 10:240-51. 2013
  3. ncbi request reprint Multiple-dose safety, pharmacokinetics, and pharmacodynamics of the μ-opioid receptor inverse agonist GSK1521498
    Pradeep J Nathan
    GlaxoSmithKline, Clinical Unit Cambridge, Addenbrooke s Hospital, Hills Road, Cambridge CB2 2GG UK
    J Clin Pharmacol 52:1456-67. 2012
  4. doi request reprint Opioid receptor modulation of hedonic taste preference and food intake: a single-dose safety, pharmacokinetic, and pharmacodynamic investigation with GSK1521498, a novel μ-opioid receptor inverse agonist
    Pradeep J Nathan
    Clinical Unit Cambridge, Cambridge, UK
    J Clin Pharmacol 52:464-74. 2012
  5. doi request reprint The effects of the dopamine D₃ receptor antagonist GSK598809 on attentional bias to palatable food cues in overweight and obese subjects
    Pradeep J Nathan
    Clinical Unit Cambridge, Medicines Discovery and Development, GlaxoSmithKline R and D, Cambridge, UK
    Int J Neuropsychopharmacol 15:149-61. 2012
  6. doi request reprint From taste hedonics to motivational drive: central μ-opioid receptors and binge-eating behaviour
    Pradeep J Nathan
    Brain Mapping Unit, Department of Psychiatry, University of Cambridge, Cambridge, UK
    Int J Neuropsychopharmacol 12:995-1008. 2009
  7. doi request reprint Effects of mu opioid receptor antagonism on cognition in obese binge-eating individuals
    Samuel R Chamberlain
    Clinical Unit Cambridge, GlaxoSmithKline, Addenbrooke s Hospital, Cambridge CB0 0QQ, UK
    Psychopharmacology (Berl) 224:501-9. 2012
  8. doi request reprint The relationship between fat mass, eating behaviour and obesity-related psychological traits in overweight and obese individuals
    Barry V O'Neill
    Experimental Medicine, GlaxoSmithKline R and D, Clinical Unit Cambridge, UK
    Appetite 59:656-61. 2012
  9. doi request reprint Effect of the dopamine D3 receptor antagonist GSK598809 on brain responses to rewarding food images in overweight and obese binge eaters
    Chris M Dodds
    Experimental Medicine, GlaxoSmithKline Pharmaceuticals, Clinical Unit Cambridge, Addenbrooke s Centre for Clinical Investigation, Box 128, Addenbrooke s Hospital, Hills Road, Cambridge CB2 2QQ, UK
    Appetite 59:27-33. 2012
  10. pmc Inhibition of opioid transmission at the μ-opioid receptor prevents both food seeking and binge-like eating
    Chiara Giuliano
    Behavioral and Clinical Neuroscience Institute and Department of Experimental Psychology, University of Cambridge, Cambridge, UK
    Neuropsychopharmacology 37:2643-52. 2012

Collaborators

Detail Information

Publications19

  1. doi request reprint The potent M(1) receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction
    Pradeep J Nathan
    Medicines Discovery and Development, GlaxoSmithKline Clinical Unit, Cambridge, UK
    Int J Neuropsychopharmacol 16:721-31. 2013
    ..Hence, selective M(1) receptor allosteric agonists may have therapeutic benefits in disorders of impaired learning including Alzheimer's disease...
  2. ncbi request reprint The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H₃ receptor antagonist in patients with mild to moderate Alzheimer's disease: a preliminary investigation
    Pradeep J Nathan
    GSK Clinical Unit Cambridge, Addenbrooke s Centre for Clinical Investigations, Cambridge Biomedical Campus, Cambridge CB2 2GG, UK
    Curr Alzheimer Res 10:240-51. 2013
    ..In this study we examined the safety, tolerability, pharmacokinetics and pro-cognitive effects of GSK239512 (oral) in patients with mild to moderate Alzheimer's disease using ascending dose titration regimens...
  3. ncbi request reprint Multiple-dose safety, pharmacokinetics, and pharmacodynamics of the μ-opioid receptor inverse agonist GSK1521498
    Pradeep J Nathan
    GlaxoSmithKline, Clinical Unit Cambridge, Addenbrooke s Hospital, Hills Road, Cambridge CB2 2GG UK
    J Clin Pharmacol 52:1456-67. 2012
    ..These findings provide encouraging safety, tolerability, and pharmacokinetic data in support of the continued clinical development of GSK1521498...
  4. doi request reprint Opioid receptor modulation of hedonic taste preference and food intake: a single-dose safety, pharmacokinetic, and pharmacodynamic investigation with GSK1521498, a novel μ-opioid receptor inverse agonist
    Pradeep J Nathan
    Clinical Unit Cambridge, Cambridge, UK
    J Clin Pharmacol 52:464-74. 2012
    ..These findings provide encouraging data in support of the development of GSK1521498 for the treatment of disorders of maladaptive ingestive behavior or compulsive consumption...
  5. doi request reprint The effects of the dopamine D₃ receptor antagonist GSK598809 on attentional bias to palatable food cues in overweight and obese subjects
    Pradeep J Nathan
    Clinical Unit Cambridge, Medicines Discovery and Development, GlaxoSmithKline R and D, Cambridge, UK
    Int J Neuropsychopharmacol 15:149-61. 2012
    ....
  6. doi request reprint From taste hedonics to motivational drive: central μ-opioid receptors and binge-eating behaviour
    Pradeep J Nathan
    Brain Mapping Unit, Department of Psychiatry, University of Cambridge, Cambridge, UK
    Int J Neuropsychopharmacol 12:995-1008. 2009
    ....
  7. doi request reprint Effects of mu opioid receptor antagonism on cognition in obese binge-eating individuals
    Samuel R Chamberlain
    Clinical Unit Cambridge, GlaxoSmithKline, Addenbrooke s Hospital, Cambridge CB0 0QQ, UK
    Psychopharmacology (Berl) 224:501-9. 2012
    ..Binge-eating represents a useful model of 'behavioural addiction' for exploring this issue...
  8. doi request reprint The relationship between fat mass, eating behaviour and obesity-related psychological traits in overweight and obese individuals
    Barry V O'Neill
    Experimental Medicine, GlaxoSmithKline R and D, Clinical Unit Cambridge, UK
    Appetite 59:656-61. 2012
    ....
  9. doi request reprint Effect of the dopamine D3 receptor antagonist GSK598809 on brain responses to rewarding food images in overweight and obese binge eaters
    Chris M Dodds
    Experimental Medicine, GlaxoSmithKline Pharmaceuticals, Clinical Unit Cambridge, Addenbrooke s Centre for Clinical Investigation, Box 128, Addenbrooke s Hospital, Hills Road, Cambridge CB2 2QQ, UK
    Appetite 59:27-33. 2012
    ..However, brain activation to food images was not modulated by GSK598809. The results demonstrate that D(3) receptor manipulation does not modulate brain responses to food images in overweight and obese subjects...
  10. pmc Inhibition of opioid transmission at the μ-opioid receptor prevents both food seeking and binge-like eating
    Chiara Giuliano
    Behavioral and Clinical Neuroscience Institute and Department of Experimental Psychology, University of Cambridge, Cambridge, UK
    Neuropsychopharmacology 37:2643-52. 2012
    ....
  11. doi request reprint Effect of dopamine D(3) receptor antagonism on approach responses to food cues in overweight and obese individuals
    Karin Mogg
    Department of Psychology, University of Southampton, Southampton, UK
    Behav Pharmacol 23:603-8. 2012
    ..The findings, albeit preliminary, are in agreement with the view that D(3) receptor antagonists may prove useful as therapeutic agents for reducing appetitive responses to food cues in obesity...
  12. doi request reprint Neural and behavioral effects of a novel mu opioid receptor antagonist in binge-eating obese people
    Victoria C Cambridge
    Department of Psychiatry, Behavioural and Clinical Neuroscience Institute, Cambridge Biomedical Campus, University of Cambridge, United Kingdom
    Biol Psychiatry 73:887-94. 2013
    ..Moreover, relatively few studies have used pharmacologic functional magnetic resonance imaging to probe the underlying basis of altered eating behaviors...
  13. doi request reprint Neuropsychiatric adverse effects of centrally acting antiobesity drugs
    Pradeep J Nathan
    Experimental Medicine, GlaxoSmithKline, Clinical Unit Cambridge, UK
    CNS Neurosci Ther 17:490-505. 2011
    ....
  14. doi request reprint The effects of alcohol on the pharmacokinetics and pharmacodynamics of the selective mu-opioid receptor antagonist GSK1521498 in healthy subjects
    Hisham Ziauddeen
    Medicines Discovery and Development, GlaxoSmithKline, Clinical Unit Cambridge, Addenbrooke s Centre for Clinical Investigations, Cambridge, UK Department of Psychiatry, Behavioural and Clinical Neuroscience Institute, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, Cambridge, UK Cambridgeshire and Peterborough NHS Foundation Trust CPFT, Cambridge, UK
    J Clin Pharmacol 53:1078-90. 2013
    ..There were no effects of GSK1521498 on reaction time, hedonic or consummatory responses. These findings provide encouraging safety and PK data to support continued development of GSK1521498 for the treatment of alcohol addiction. ..
  15. doi request reprint Effects of donepezil on cognitive performance after sleep deprivation
    Chris M Dodds
    Clinical Unit Cambridge, Medicines Discovery and Development, GlaxoSmithKline R and D, Cambridge, UK
    Hum Psychopharmacol 26:578-87. 2011
    ....
  16. pmc Attention to language: novel MEG paradigm for registering involuntary language processing in the brain
    Yury Shtyrov
    Medical Research Council, Cognition and Brain Sciences Unit, Cambridge, UK
    Neuropsychologia 50:2605-16. 2012
    ..It does it in an automatic and task-free fashion, indicating its potential benefit for assessing uncooperative clinical populations...
  17. pmc Distinct modulatory effects of satiety and sibutramine on brain responses to food images in humans: a double dissociation across hypothalamus, amygdala, and ventral striatum
    Paul C Fletcher
    Department of Psychiatry, University of Cambridge, GlaxoSmithKline Clinical Unit Cambridge, Addenbrooke s Centre for Clinical Investigations, Addenbrooke s Hospital, Cambridge CB2 2QQ, United Kingdom
    J Neurosci 30:14346-55. 2010
    ..Furthermore, they support a regionally specific effect on brain function through which sibutramine exerts its clinical effect...
  18. doi request reprint Studying synaptic plasticity in the human brain and opportunities for drug discovery
    Pradeep J Nathan
    Medicines Discovery and Development, GlaxoSmithKline Clinical Unit, Cambridge, United Kingdom
    Curr Opin Pharmacol 11:540-8. 2011
    ....
  19. doi request reprint Differential cognitive deterioration in dementia: a two year longitudinal study
    Samuel R Chamberlain
    Department of Psychiatry, University of Cambridge School of Clinical Medicine, Addenbrooke s Hospital, Cambridge, UK
    J Alzheimers Dis 24:125-36. 2011
    ..Follow-up studies in independent populations are needed to validate predictive algorithms identified...